小金片致严重肝损伤1例分析

doi:10.19803/j.1672-8629.2022.02.22

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (2): 213-216.
DOI: 10.19803/j.1672-8629.2022.02.22

小金片致严重肝损伤1例分析

杨晓露, 曹姗, 熊波, 秦臻, 夏云, 曲虹^*

上海市宝山区中西医结合医院药剂科,上海 201999

收稿日期:2020-03-30 出版日期:2022-02-15 发布日期:2022-02-15
通讯作者: ^*曲虹,女,本科,副主任药师,临床药学。E-mail：quhong6988@sina.com
作者简介:杨晓露,女,硕士,主管中药师,临床药学。

One case of serious liver injury induced by Xiaojin tablets

YANG Xiaolu, CAO Shan, XIONG Bo, QIN Zhen, XIA Yun, QU Hong^*

Department of Pharmacy, Baoshan Hospital of Traditional Chinese and Western Medicine, Shanghai 201999, China

Received:2020-03-30 Online:2022-02-15 Published:2022-02-15

摘要/Abstract

摘要： 目的探讨严重肝功能损伤与小金片的相关性。方法通过1例服用小金片导致严重肝损伤的不良反应,分析与小金片的相关性,通过查找文献分析其中药成分及制剂导致不良反应的机制。结果根据《中草药相关肝损伤临床诊疗指南》的RUCAM表,将患者评定为药物性肝损伤,肝细胞损伤型,慢性,RUCAM 8 分（很可能）,严重程度3级。结论小金片引起的严重肝损伤与患者自身免疫、药品成分、质量标准等有关。

关键词: 小金片, 肝损伤, 草乌, 药品不良反应

Abstract: Objective To explore the correlations between serious liver function injury and Xiaojin tablets. Methods The adverse reactions of one case of serious liver injury caused by Xiaojin tablets were analyzed to study the correlation with Xiaojin tablets. The mechanism by which the medicinal ingredients and preparations caused adverse reactions was investigated by searching literature. Results According to the RUCAM table specified in the Guidelines for Clinical Diagnosis and Treatment of Herb-induced Liver Injury, this patient was diagnosed with chronic drug-induced liver cell injury. The RUCAM score was 8 (most likely), and the severity level was 3. The side effects of Xiaojin tablets might have been related to the toxic components. Conclusion The serious liver injury caused by Xiaojin tablets is related to the patient's autoimmunity, drug composition and quality standard.

Key words: Xiaojin tablet, liver injury, Aconitum kusnezoffii Reichb, adverse drug reaction

中图分类号:

R969R994.11

杨晓露, 曹姗, 熊波, 秦臻, 夏云, 曲虹. 小金片致严重肝损伤1例分析[J]. 中国药物警戒, 2022, 19(2): 213-216.

YANG Xiaolu, CAO Shan, XIONG Bo, QIN Zhen, XIA Yun, QU Hong. One case of serious liver injury induced by Xiaojin tablets[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 213-216.

参考文献

[1] HU BG.Clinical investigation of adverse reactions induced by Xiaojin pills and Xiaojin capsules[J]. Gansu Science and Technology(甘肃科技), 2018, 34(20): 163-164.
[2] TIAN ZP.Drug use analysis of Xiaojin pills and consideration of rational drug use in our hospital[D]. Beijing University of Chinese Medicine, 2019.
[3] ZHANG Z, ZHANG JL.Analysis of 45 cases of adverse drug reaction induced by Xiaojinwan and Xiaojinjiaonang[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2012, 9(4): 242-244.
[4] MENG ZX.Cholestatic hepatitis following combined use of Xiaojin pill and Rupixiao tablet[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2004(4): 256-257.
[5] YU LC, MAO YM, CHEN CW.Guidelines for the diagnosis and treatment of drug-induced liver injury[J]. J Prac Hepatol(实用肝脏病杂志), 2017, 20(2): 257-274.
[6] CHALASANI NP, HAYASHI PH, BONKOVSKY HL, et al.ACG clinical guideline: the diagnosis and management of idiosyncratic drug- induced liver injury[J]. Am J Gastroenterol, 2014, 109(7): 950-966.
[7] XIAO XH, LI XH, ZHU Y, et al.Guideline for diagnosis and treatment of herbinduced liver injury[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2016, 41(7): 1165-1172.
[8] ZHANG XM, LI F, ZHANG B, et al.Data-mining characteristics of adverse drug reactions and pharmacovigilance of Chinese patent drugs including aconitum herbs[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2018, 43(2): 216-221.
[9] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People's Republic of China(中华人民共和国药典)[S]. Beijing: China Pharmace-utical Science and Technology Publishing House, 2015: 270.
[10] WANG H, FU Q, WANG XM.Analysis of toxicity and side effects of mubiezi decoction containing excess[J]. Beijing Journal of Traditional Chinese Medicine(北京中医药), 2011, 30(12): 942-944.
[11] SONG H.Preliminary study on the mechanism of“significant attenuation and synergistic effect”and processing technology of momordicae-semen cream[D]. Anhui University of Chinese Medicine, 2019.
[12] WANG Y,ZHANG B, LIN ZJ, et al.Chinese materia medica for inducing resuscitation: safety analysis and pharmacovigilance considerations[J]. China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志), 2016, 31(9): 3646-3649.
[13] ZHANG CG.Two cases of drug eruption caused by, wulingzhi and myrrh[J]. Heilongjiang Journal of Traditional Chinese Medicine(黑龙江中医药), 1999(2): 34.
[14] WANG Y, ZHANG B, LIN ZJ, et al.Chinese materia medica for suppressing hyperactive liver and calming endogenous wind: Safety analysis and pharmacovigilance considerations[J]. China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志), 2016, 31(11): 4643-4648.
[15] MA QF.Analysis of clinical adverse reactions and toxicity of frankincense myrrh [J/OL]. Cardiovascular Disease Journal of Integrated Traditional Chinese and Western Medicine(中西医结合心血管病电子杂志), 2018, 6(4): 23.
[16] WANG D.Comprehensive safety evaluation of Radix Aconiti kusnezoffii based on literature research[D]. Beijing University of Chinese Medicine, 2019.

小金片致严重肝损伤1例分析

One case of serious liver injury induced by Xiaojin tablets

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	王欣, 史磊磊, 张雨涵, 谢允东, 刘继平. 多药耐药相关蛋白转运体在药物性肝损伤中的作用研究进展[J]. 中国药物警戒, 2024, 21(2): 229-234.
[9]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[10]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[11]	高源, 石伟, 肖小河, 柏兆方, 王伽伯. 特异质型药物性肝损伤体内评价模型研究进展[J]. 中国药物警戒, 2024, 21(1): 33-39.
[12]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[13]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[14]	詹姆斯·布坎南. 用 nR 改良海氏法则及 P_ALT 评估药物性肝损伤研究进展[J]. 中国药物警戒, 2024, 21(1): 117-120.
[15]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.